Trastuzumab deruxtecan biosimilar(Samsung Bioepis Co Ltd)

N/A

Report date: 2026/02/12 20:00:14

Base Information

Drug NameTrastuzumab deruxtecan biosimilar(Samsung Bioepis Co Ltd)
Drug Alias NameSB38SB-38
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonistsDNA topoisomerase I inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2DNA topoisomerase I
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSamsung Bioepis Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A